OA12889A - Pramipexole once-daily dosage form. - Google Patents

Pramipexole once-daily dosage form. Download PDF

Info

Publication number: OA12889A
Authority: OA; OAPI
Prior art keywords: composition; pramipexole; hours; absorption; release
Prior art date: 2002-07-25

Application number

OA1200500017A

Other languages

English (en)

Inventor

Ernest J Lee

Gerard M Bredael

John R Baldwin

Steven R Cox

Mark J Heintz

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-25

Publication date

2006-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31192088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-25 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2006-10-13 Publication of OA12889A publication Critical patent/OA12889A/en

Links

FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims abstract description 87
229960003089 pramipexole Drugs 0.000 title claims abstract description 79
239000002552 dosage form Substances 0.000 title description 14
239000000203 mixture Substances 0.000 claims abstract description 100
238000010521 absorption reaction Methods 0.000 claims abstract description 37
238000001727 in vivo Methods 0.000 claims abstract description 29
238000000338 in vitro Methods 0.000 claims abstract description 26
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
238000007922 dissolution test Methods 0.000 claims abstract description 10
239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 9
229940098778 Dopamine receptor agonist Drugs 0.000 claims abstract description 8
230000001747 exhibiting effect Effects 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
239000011248 coating agent Substances 0.000 claims description 45
238000000576 coating method Methods 0.000 claims description 45
238000004090 dissolution Methods 0.000 claims description 26
238000012360 testing method Methods 0.000 claims description 20
238000009472 formulation Methods 0.000 claims description 19
229960002652 pramipexole dihydrochloride Drugs 0.000 claims description 16
VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
208000018737 Parkinson disease Diseases 0.000 claims description 8
229920000642 polymer Polymers 0.000 claims description 8
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 7
230000036470 plasma concentration Effects 0.000 claims description 7
239000012738 dissolution medium Substances 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 5
239000008363 phosphate buffer Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
150000004682 monohydrates Chemical class 0.000 claims description 2
241000206607 Porphyra umbilicalis Species 0.000 claims 1
230000003204 osmotic effect Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 3
239000003826 tablet Substances 0.000 description 106
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 37
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 37
229920002472 Starch Polymers 0.000 description 29
235000019698 starch Nutrition 0.000 description 29
239000008107 starch Substances 0.000 description 24
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 21
239000000463 material Substances 0.000 description 20
239000007787 solid Substances 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
239000001856 Ethyl cellulose Substances 0.000 description 12
229920000881 Modified starch Polymers 0.000 description 12
230000006835 compression Effects 0.000 description 12
238000007906 compression Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
229920001249 ethyl cellulose Polymers 0.000 description 12
235000019325 ethyl cellulose Nutrition 0.000 description 12
239000007939 sustained release tablet Substances 0.000 description 12
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 11
229920001477 hydrophilic polymer Polymers 0.000 description 10
238000000034 method Methods 0.000 description 10
229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 10
230000000694 effects Effects 0.000 description 9
239000012730 sustained-release form Substances 0.000 description 9
238000013268 sustained release Methods 0.000 description 8
208000035475 disorder Diseases 0.000 description 7
229940101972 mirapex Drugs 0.000 description 7
239000000377 silicon dioxide Substances 0.000 description 7
235000012239 silicon dioxide Nutrition 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000010410 layer Substances 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
208000001089 Multiple system atrophy Diseases 0.000 description 5
206010031127 Orthostatic hypotension Diseases 0.000 description 5
230000004584 weight gain Effects 0.000 description 5
235000019786 weight gain Nutrition 0.000 description 5
230000002411 adverse Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000035882 stress Effects 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
238000013265 extended release Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
238000010998 test method Methods 0.000 description 3
229920000856 Amylose Polymers 0.000 description 2
235000008733 Citrus aurantifolia Nutrition 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010053317 Hydrophobia Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
235000011941 Tilia x europaea Nutrition 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000005336 cracking Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000007547 defect Effects 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
239000004571 lime Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
APVQOOKHDZVJEX-QTPLPEIMSA-N pramipexole hydrochloride Chemical compound O.Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-QTPLPEIMSA-N 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940033134 talc Drugs 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229920003176 water-insoluble polymer Polymers 0.000 description 2
DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010040981 Sleep attacks Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000011436 cob Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000006837 decompression Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229940002658 differin Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000013563 matrix tablet Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
-1 polymorphs Chemical class 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001812 pycnometry Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
VOJRMYBBPKNLLI-ORHWHDKWSA-N sumanirole maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 VOJRMYBBPKNLLI-ORHWHDKWSA-N 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200500017A 2002-07-25 2003-07-25 Pramipexole once-daily dosage form. OA12889A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39844702P	2002-07-25	2002-07-25
US39842702P	2002-07-25	2002-07-25
US47951403P	2003-06-18	2003-06-18

Publications (1)

Publication Number	Publication Date
OA12889A true OA12889A (en)	2006-10-13

Family

ID=31192088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500017A OA12889A (en)	2002-07-25	2003-07-25	Pramipexole once-daily dosage form.

Country Status (39)

Country	Link
US (2)	US8679533B2 (is)
EP (2)	EP2289514B9 (is)
JP (1)	JP4607584B2 (is)
KR (2)	KR20050025654A (is)
CN (1)	CN1671381B (is)
AP (1)	AP2223A (is)
AR (1)	AR040682A1 (is)
AU (1)	AU2003256921B2 (is)
BR (1)	BR0312948A (is)
CA (1)	CA2493629C (is)
CU (1)	CU23468B7 (is)
CY (2)	CY1114263T1 (is)
DE (1)	DE20321906U1 (is)
DK (2)	DK1536792T3 (is)
EA (1)	EA017595B1 (is)
EC (1)	ECSP055569A (is)
ES (2)	ES2421787T3 (is)
GE (1)	GEP20074047B (is)
HR (1)	HRP20041234B1 (is)
IL (1)	IL166076A0 (is)
IS (1)	IS7613A (is)
MA (1)	MA27372A1 (is)
ME (1)	ME00347B (is)
MX (1)	MXPA05000980A (is)
MY (1)	MY142204A (is)
NO (1)	NO20050481L (is)
NZ (1)	NZ562681A (is)
OA (1)	OA12889A (is)
PA (1)	PA8578501A1 (is)
PE (1)	PE20040134A1 (is)
PL (1)	PL375444A1 (is)
PT (2)	PT2289514E (is)
RS (1)	RS52764B (is)
SG (1)	SG177011A1 (is)
SI (2)	SI2289514T1 (is)
TW (1)	TWI351955B (is)
UY (1)	UY27913A1 (is)
WO (1)	WO2004010999A1 (is)
ZA (1)	ZA200500015B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
US7365086B2 (en) *	2003-07-25	2008-04-29	Synthon Ip Inc.	Pramipexole acid addition salts
NZ553561A (en) *	2004-08-13	2010-12-24	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553645A (en) *	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
KR20070058540A (ko) *	2004-10-01	2007-06-08	니폰 조키 세야쿠 가부시키가이샤	고형 의약제제
WO2006046256A1 (en) *	2004-10-27	2006-05-04	Alembic Limited	Extended release formulation of pramipexole dihydrochloride
WO2007090882A2 (en) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) *	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
US20090098202A1 (en) *	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
US8518926B2 (en) *	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl) *	2006-05-16	2012-05-31	Knopp Neurosciences Inc	Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
US20080254118A1 (en) *	2007-04-11	2008-10-16	Hans-Werner Wernersbach	Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008103420A1 (en)	2007-02-21	2008-08-28	The Regents Of The University Of Michigan	Compositions and methods for tranquilizing heart muscle
EP2137171A4 (en)	2007-03-14	2010-05-19	Knopp Neurosciences Inc	SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
CA2688074A1 (en) *	2007-05-25	2008-12-04	Boehringer Ingelheim International Gmbh	Pharmaceutical formulation comprising pramipexole
US20080299189A1 (en) *	2007-06-04	2008-12-04	Drugtech Corporation	Controlled release dopamine agonist compositions
CA2725482A1 (en) *	2008-06-09	2009-12-17	Supernus Pharmaceuticals, Inc.	Controlled release formulations of pramipexole
US20110190356A1 (en)	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
AU2010234244A1 (en) *	2009-04-09	2011-10-13	Purdue Pharma	Once-daily oral IR/CR pramipexole formulation
EP2448411A4 (en) *	2009-07-02	2012-11-28	Supernus Pharmaceuticals Inc	METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011037976A2 (en) *	2009-09-22	2011-03-31	Dr. Reddy's Laboratories Limited	Pramipexole pharmaceutical formulations
EP2525786A2 (en) *	2010-01-18	2012-11-28	Synthon BV	Pramipexole extended release tablets
TR201001862A1 (tr) *	2010-03-11	2011-10-21	Sanovel �La� San.Ve T�C.A.�.	Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
WO2011128914A2 (en)	2010-04-15	2011-10-20	Cadila Healthcare Limited	Extended release pharmaceutical compositions of pramipexole
AU2011256928A1 (en)	2010-05-24	2012-12-20	Lupin Limited	Extended release formulation of pramipexole
CN102670550A (zh) *	2011-03-14	2012-09-19	北京天衡药物研究院	盐酸普拉克索渗透泵型控释片
WO2013034173A1 (en)	2011-09-06	2013-03-14	Synthon Bv	Pramipexole extended release tablets
CN102406626B (zh) *	2011-12-02	2013-08-28	深圳海王药业有限公司	盐酸普拉克索缓释片剂及其制备方法
US9512096B2 (en)	2011-12-22	2016-12-06	Knopp Biosciences, LLP	Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de)	2012-11-15	2014-05-21	Aristo Pharma GmbH	Pramipexol-Retardtablettenformulierung
CN103435571B (zh) *	2012-11-22	2015-12-09	北京三泉医药技术有限公司	四氢苯并噻唑衍生物及其制备方法
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
HRP20251187T1 (hr)	2013-07-12	2025-11-21	Areteia Therapeutics, Inc.	Liječenje povišenih razina eozinofila i/ili bazofila
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en)	2013-08-13	2017-05-09	Knopp Biosciences, Llc	Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9763918B2 (en)	2013-08-13	2017-09-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
CN104606162B (zh) *	2015-01-07	2017-03-29	海南康虹医药科技开发有限公司	一种盐酸普拉克索缓释制剂及其制备方法
CN104784155B (zh) *	2015-05-15	2018-02-23	中国药科大学	一种盐酸普拉克索组合微丸胶囊及其制备方法
CN105030721B (zh) *	2015-08-30	2018-05-04	南京康川济医药科技有限公司	一种含有盐酸普拉克索的口服固体组合物
CN114668747A (zh) *	2016-10-07	2022-06-28	全崴生技股份有限公司	普拉克索经皮贴片系统与用法
CN110402304A (zh) *	2016-12-21	2019-11-01	哈索赫伯特施密特有限两合公司	用于酸洗合成材料的酸洗液
EP3615024B1 (en) *	2017-04-24	2026-02-18	Alto Neuroscience, Inc.	Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
US10912560B2 (en)	2017-06-23	2021-02-09	Lexington Medical, Inc.	Surgical reloadable cartridge assembly
WO2019036624A1 (en) *	2017-08-17	2019-02-21	Gu Zi Qiang	MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
US11298131B2 (en)	2020-01-15	2022-04-12	Lexington Medical, Inc.	Multidirectional apparatus
US11116501B1 (en)	2020-04-10	2021-09-14	Lexington Medical, Inc.	Surgical handle articulation assemblies
US12508020B2 (en)	2022-02-11	2025-12-30	Lexington Medical, Inc.	Blade assembly for a surgical reloadable cartridge assembly
US20250205207A1 (en) *	2023-12-20	2025-06-26	Areteia Therapeutics, Inc.	Matrix tablets of dexpramipexole and methods of manufacturing and use thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2887440A (en)	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
US3065143A (en)	1960-04-19	1962-11-20	Richardson Merrell Inc	Sustained release tablet
NL265428A (is)	1960-06-06
US3458622A (en)	1967-04-07	1969-07-29	Squibb & Sons Inc	Controlled release tablet
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) *	1975-07-24	1983-01-06	武田薬品工業株式会社	Ｌ− アスコルビンサンセイザイノセイゾウホウ
US4140755A (en) *	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
US4167558A (en)	1976-02-13	1979-09-11	Hoffmann-La Roche Inc.	Novel sustained release tablet formulations
SE8003805L (sv)	1980-05-21	1981-11-22	Haessle Ab	En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8103843L (sv) *	1981-06-18	1982-12-19	Astra Laekemedel Ab	Farmaceutisk mixtur
US4424235A (en) *	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en)	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3572485D1 (en)	1984-12-22	1989-09-28	Thomae Gmbh Dr K	Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4738851A (en) *	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US4666612A (en)	1986-03-17	1987-05-19	Kerr-Mcgee Chemical Corporation	Method for recovering a wood preservative from waste sludges
US4772473A (en)	1986-06-16	1988-09-20	Norwich Eaton Pharmaceuticals, Inc.	Nitrofurantoin dosage form
US4709712A (en) *	1986-10-22	1987-12-01	Dermatalogical Products Of Texas	Polycarboxylic acid polymer gels as protective agents
US4968508A (en)	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
US4789549A (en)	1987-03-09	1988-12-06	Warner-Lambert Company	Sustained release dosage forms
US4859470A (en)	1988-06-02	1989-08-22	Alza Corporation	Dosage form for delivering diltiazem
GB8828020D0 (en) *	1988-12-01	1989-01-05	Unilever Plc	Topical composition
US5026559A (en) *	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5007790A (en)	1989-04-11	1991-04-16	Depomed Systems, Inc.	Sustained-release oral drug dosage form
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5273975A (en) *	1989-06-09	1993-12-28	The Upjohn Company	Heterocyclic amines having central nervous system activity
FR2653337B1 (fr)	1989-10-23	1992-02-07	Dow Corning Sa	Element a liberation prolongee et procede pour le fabriquer.
IE82916B1 (en)	1990-11-02	2003-06-11	Elan Corp Plc	Formulations and their use in the treatment of neurological diseases
EP0447168A3 (en)	1990-03-16	1993-01-07	Yamanouchi Pharmaceutical Co. Ltd.	Long acting granular pharmaceutical composition
US5472712A (en)	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en)	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en)	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
US5731338A (en)	1992-07-02	1998-03-24	Oramed, Inc.	Controlled release pilocarpine delivery system
JP3140465B2 (ja)	1992-09-18	2001-03-05	山之内製薬株式会社	ハイドロゲル徐放性製剤
DE4241013A1 (de)	1992-12-05	1994-06-09	Boehringer Ingelheim Kg	Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en)	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
US5484608A (en)	1994-03-28	1996-01-16	Pharmavene, Inc.	Sustained-release drug delivery system
DE4432757A1 (de)	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5650420A (en)	1994-12-15	1997-07-22	Pharmacia & Upjohn Company	Pramipexole as a neuroprotective agent
WO1997004752A1 (en)	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
PT869772E (pt)	1995-12-27	2002-03-28	Janssen Pharmaceutica Nv	Forma galenica solida bioadesiva
US5846971A (en)	1996-06-28	1998-12-08	Schering Corporation	Oral antifungal composition
JPH1017497A (ja)	1996-07-02	1998-01-20	Takeda Chem Ind Ltd	徐放性製剤およびその製造方法
GB9619074D0 (en)	1996-09-12	1996-10-23	Smithkline Beecham Plc	Composition
ES2248908T7 (es) *	1997-06-06	2014-11-24	Depomed, Inc.	Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU8293498A (en)	1997-07-02	1999-01-25	Euro-Celtique S.A.	Stabilized sustained release tramadol formulations
CA2211778A1 (en)	1997-08-14	1999-02-14	Francois Carriere	Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
DE69819748T2 (de) *	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) *	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6248358B1 (en) *	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
ATE239447T1 (de)	1997-09-29	2003-05-15	Inhale Therapeutic Syst	In verneblern verwendbare, stabilisierte zubereitungen
US6197339B1 (en)	1997-09-30	2001-03-06	Pharmacia & Upjohn Company	Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en)	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en)	1997-10-28	2002-01-31	Wilson Leland F.	As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en)	2000-05-11	2002-05-09	Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi	Novel oral dosage form for carvedilol
FR2772615B1 (fr)	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
GB9802201D0 (en)	1998-02-03	1998-04-01	Cerestar Holding Bv	Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
NZ505807A (en) *	1998-03-11	2003-01-31	Smithkline Beecham Corp	Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
DE69928521T2 (de)	1998-05-15	2006-07-27	Pharmacia & Upjohn Co. Llc, Kalamazoo	Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
US6312728B1 (en)	1998-07-07	2001-11-06	Cascade Development, Inc.	Sustained release pharmaceutical preparation
TW407058B (en) *	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
US20010055613A1 (en)	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
US6270805B1 (en)	1998-11-06	2001-08-07	Andrx Pharmaceuticals, Inc.	Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HRP20010700B1 (hr) *	1999-03-31	2011-01-31	Janssen Pharmaceutica N.V.	Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
DE19927688A1 (de) *	1999-06-17	2000-12-21	Gruenenthal Gmbh	Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
AU779955B2 (en)	1999-07-13	2005-02-24	Alpha Research Group, Llc	Compositions and methods for the treatment of Parkinson's disease
GB9923045D0 (en)	1999-09-29	1999-12-01	Novartis Ag	New oral formulations
WO2001022820A1 (en)	1999-09-30	2001-04-05	The General Hospital Corporation	Use of pramipexole as a treatment for cocaine craving
EP1225888A2 (en)	1999-10-19	2002-07-31	Nps Pharmaceuticals, Inc.	Sustained-release formulations for treating cns-mediated disorders
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1434713A (zh)	1999-12-22	2003-08-06	法马西亚公司	环加氧酶－2抑制剂的缓释制剂
CA2332691C (en)	2000-01-27	2007-11-27	The York Group, Inc.	Death care merchandising system
EP2517710B1 (en)	2000-02-08	2015-03-25	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
PE20011074A1 (es)	2000-02-23	2001-10-04	Upjohn Co	Uso de pramipexol en el tratamiento de trastornos de adiccion
CN1660435A (zh) *	2000-02-24	2005-08-31	法玛西雅厄普约翰美国公司	新的药物联合形式
US6955821B2 (en)	2000-04-28	2005-10-18	Adams Laboratories, Inc.	Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en)	2000-04-28	2002-04-16	Adams Laboratories, Inc.	Guaifenesin sustained release formulation and tablets
US6277875B1 (en)	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
AU2001286418A1 (en)	2000-08-08	2002-02-18	Teva Pharmaceutical Industries Ltd.	Stable pergolide mesylate and process for making same
ES2187249B1 (es) *	2000-09-18	2004-09-16	Synthon Bv	Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) *	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
PL370793A1 (en)	2001-07-04	2005-05-30	Sun Pharmaceutical Industries Limited	Gastric retention controlled drug delivery system
FR2827872A1 (fr)	2001-07-30	2003-01-31	Roussy Inst Gustave	Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US20030032661A1 (en)	2001-08-02	2003-02-13	Boehringer Ingelheim Pharma Kg	Pramipexole as an anticonvulsant
GB0125088D0 (en)	2001-10-18	2001-12-12	Smithkline Beecham Cork Ltd	New use
US20030133982A1 (en) *	2001-12-20	2003-07-17	Heimlich John M.	Zero-order sustained release dosage forms and method of making same
US20030224050A1 (en)	2002-01-04	2003-12-04	Charles Chiao	Drug delivery system for sustained delivery of glipizide
US7943575B2 (en)	2002-03-04	2011-05-17	Ipsen Pharma S.A.S.	Sustained release drug formulations containing a carrier peptide
LT2425824T (lt)	2002-04-05	2017-07-25	Euro-Celtique S.A.	Farmacinis preparatas, turintis oksikodono ir naloksono
JP5466346B2 (ja)	2002-04-15	2014-04-09	レキットベンキーザーエルエルシー	グアイフェネシン組合せ剤の徐放
US20030215498A1 (en)	2002-05-17	2003-11-20	Harland Ronald S.	Rapidly disintegrating comressed tablets comprising biologically active compounds
BR0311693A (pt)	2002-06-10	2005-03-22	Wyeth Corp	Sal de formato de o-desmetil-venlafaxina
CA2489295A1 (en)	2002-06-27	2004-01-08	Cilag Ag	Spherical pellet containing a water-soluble active ingredient
AU2003281181A1 (en)	2002-07-11	2004-02-02	Takeda Pharmaceutical Company Limited	Process for producing coated preparation
CA2488860A1 (en)	2002-07-25	2004-02-05	Pharmacia Corporation	Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
MY136318A (en) *	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
US20050226926A1 (en) *	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
US20040132826A1 (en) *	2002-10-25	2004-07-08	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
CA2415154C (en)	2002-12-24	2009-06-16	Biovail Laboratories Inc.	Modified release formulations of selective serotonin re-uptake inhibitors
AU2002361495A1 (en)	2002-12-24	2004-07-22	Lupin Limited	Enteric coated fluoxetine composition
US20050020589A1 (en) *	2003-06-18	2005-01-27	Pfizer Inc.	Sustained-release tablet composition comprising a dopamine receptor agonist
NZ553561A (en)	2004-08-13	2010-12-24	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553645A (en) *	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US20090098202A1 (en) *	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
US20090041844A1 (en) *	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
EP1886665A1 (en) *	2006-08-01	2008-02-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Gastro retentive delivery system
CL2007002214A1 (es)	2006-08-14	2008-03-07	Boehringer Ingelheim Int	Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2056797A2 (en)	2006-08-25	2009-05-13	Boehringer Ingelheim International GmbH	Controlled release system and method for manufacturing the same

2003
- 2003-07-24 PE PE2003000736A patent/PE20040134A1/es not_active Application Discontinuation
- 2003-07-24 US US10/626,275 patent/US8679533B2/en active Active
- 2003-07-24 AR AR20030102667A patent/AR040682A1/es unknown
- 2003-07-24 MY MYPI20032783A patent/MY142204A/en unknown
- 2003-07-24 PA PA20038578501A patent/PA8578501A1/es unknown
- 2003-07-25 PT PT101740892T patent/PT2289514E/pt unknown
- 2003-07-25 RS RS115104A patent/RS52764B/sr unknown
- 2003-07-25 KR KR1020057001294A patent/KR20050025654A/ko not_active Ceased
- 2003-07-25 EA EA200500080A patent/EA017595B1/ru not_active IP Right Cessation
- 2003-07-25 BR BR0312948-9A patent/BR0312948A/pt not_active IP Right Cessation
- 2003-07-25 JP JP2004524936A patent/JP4607584B2/ja not_active Expired - Fee Related
- 2003-07-25 PT PT37719598T patent/PT1536792E/pt unknown
- 2003-07-25 KR KR1020077012380A patent/KR101066374B1/ko not_active Expired - Fee Related
- 2003-07-25 CA CA2493629A patent/CA2493629C/en not_active Expired - Fee Related
- 2003-07-25 GE GEAP8598A patent/GEP20074047B/en unknown
- 2003-07-25 WO PCT/US2003/023522 patent/WO2004010999A1/en not_active Ceased
- 2003-07-25 NZ NZ562681A patent/NZ562681A/en not_active IP Right Cessation
- 2003-07-25 ES ES10174089T patent/ES2421787T3/es not_active Expired - Lifetime
- 2003-07-25 MX MXPA05000980A patent/MXPA05000980A/es unknown
- 2003-07-25 SG SG2008086357A patent/SG177011A1/en unknown
- 2003-07-25 DK DK03771959.8T patent/DK1536792T3/da active
- 2003-07-25 SI SI200332276T patent/SI2289514T1/sl unknown
- 2003-07-25 ME MEP-2008-522A patent/ME00347B/me unknown
- 2003-07-25 AU AU2003256921A patent/AU2003256921B2/en not_active Expired
- 2003-07-25 TW TW092120436A patent/TWI351955B/zh not_active IP Right Cessation
- 2003-07-25 OA OA1200500017A patent/OA12889A/en unknown
- 2003-07-25 HR HRP20041234AA patent/HRP20041234B1/hr not_active IP Right Cessation
- 2003-07-25 ES ES03771959.8T patent/ES2436745T3/es not_active Expired - Lifetime
- 2003-07-25 EP EP10174089.2A patent/EP2289514B9/en not_active Expired - Lifetime
- 2003-07-25 CN CN038178311A patent/CN1671381B/zh not_active Expired - Fee Related
- 2003-07-25 EP EP03771959.8A patent/EP1536792B1/en not_active Expired - Lifetime
- 2003-07-25 SI SI200332311T patent/SI1536792T1/sl unknown
- 2003-07-25 DE DE20321906U patent/DE20321906U1/de not_active Expired - Lifetime
- 2003-07-25 DK DK10174089.2T patent/DK2289514T5/da active
- 2003-07-25 PL PL03375444A patent/PL375444A1/xx unknown
- 2003-07-25 AP AP2005003206A patent/AP2223A/xx active
- 2003-07-31 UY UY27913A patent/UY27913A1/es not_active Application Discontinuation
2004
- 2004-12-23 IS IS7613A patent/IS7613A/is unknown
- 2004-12-30 IL IL16607604A patent/IL166076A0/xx unknown
2005
- 2005-01-03 ZA ZA200500015A patent/ZA200500015B/en unknown
- 2005-01-24 EC EC2005005569A patent/ECSP055569A/es unknown
- 2005-01-25 CU CU20050019A patent/CU23468B7/es unknown
- 2005-01-25 MA MA28067A patent/MA27372A1/fr unknown
- 2005-01-27 NO NO20050481A patent/NO20050481L/no not_active Application Discontinuation
2013
- 2013-07-26 CY CY20131100643T patent/CY1114263T1/el unknown
- 2013-11-01 CY CY20131100969T patent/CY1114566T1/el unknown
2014
- 2014-01-28 US US14/165,743 patent/US20140141079A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2289514B1 (en)	2013-06-19
JP4607584B2 (ja)	2011-01-05
EP1536792B1 (en)	2013-09-18
NO20050481L (no)	2005-01-27
AP2223A (en)	2011-03-24
EA017595B1 (ru)	2013-01-30
ES2421787T3 (es)	2013-09-05
NZ562681A (en)	2009-11-27
AU2003256921B2 (en)	2009-03-05
CA2493629A1 (en)	2004-02-05
MY142204A (en)	2010-10-29
EP2289514B9 (en)	2013-08-21
RS52764B (sr)	2013-10-31
PA8578501A1 (es)	2005-02-04
CU23468B7 (es)	2009-12-17
JP2005538995A (ja)	2005-12-22
KR20070062614A (ko)	2007-06-15
AP2005003206A0 (en)	2005-03-31
CA2493629C (en)	2013-10-08
IL166076A0 (en)	2006-01-15
UY27913A1 (es)	2004-02-27
CN1671381B (zh)	2010-10-27
ZA200500015B (en)	2006-07-26
HRP20041234A2 (en)	2005-04-30
US8679533B2 (en)	2014-03-25
BR0312948A (pt)	2005-06-14
DK1536792T3 (da)	2013-11-11
KR101066374B1 (ko)	2011-09-20
ECSP055569A (es)	2005-04-18
DE20321906U1 (de)	2012-11-07
US20050175691A1 (en)	2005-08-11
TW200418465A (en)	2004-10-01
DK2289514T3 (da)	2013-08-05
MA27372A1 (fr)	2005-06-01
ES2436745T3 (es)	2014-01-07
SI2289514T1 (sl)	2013-08-30
PT1536792E (pt)	2013-12-02
CY1114566T1 (el)	2016-10-05
SG177011A1 (en)	2012-01-30
EP2289514A1 (en)	2011-03-02
DK2289514T5 (da)	2013-09-30
TWI351955B (en)	2011-11-11
HK1078007A1 (en)	2006-03-03
CN1671381A (zh)	2005-09-21
KR20050025654A (ko)	2005-03-14
MXPA05000980A (es)	2005-09-12
RS115104A (sr)	2006-12-15
AR040682A1 (es)	2005-04-13
EP1536792A1 (en)	2005-06-08
SI1536792T1 (sl)	2013-11-29
US20140141079A1 (en)	2014-05-22
HRP20041234B1 (hr)	2013-07-31
WO2004010999A1 (en)	2004-02-05
PE20040134A1 (es)	2004-03-06
EA200500080A1 (ru)	2005-06-30
AU2003256921A1 (en)	2004-02-16
GEP20074047B (en)	2007-02-26
CY1114263T1 (el)	2016-08-31
IS7613A (is)	2004-12-23
MEP52208A (en)	2011-02-10
PL375444A1 (en)	2005-11-28
ES2421787T9 (es)	2013-11-06
PT2289514E (pt)	2013-07-23
ME00347B (me)	2011-05-10

Publication	Publication Date	Title
OA12889A (en)	2006-10-13	Pramipexole once-daily dosage form.
CA2492854C (en)	2009-10-20	Sustained-release tablet composition of pramipexole
EP1536791B1 (en)	2010-01-27	Sustained-release tablet comprising reboxetine
HK1078007B (en)	2011-01-14	Pramipexole once-daily dosage form